Luke S Benz1, Margaret R Wrensch2,3, Joellen M Schildkraut4, Melissa L Bondy5, Joshua L Warren1, Joseph L Wiemels3, Elizabeth B Claus1,6. 1. Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, Connecticut. 2. Department of Neurological Surgery, University of California at San Francisco, San Francisco, California. 3. Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California. 4. Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia. 5. Section of Epidemiology and Popular Sciences, Department of Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. 6. Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: To the authors' knowledge, limited data exist regarding long-term quality of life (QOL) for patients diagnosed with intracranial meningioma. METHODS: The data in the current study concerned 1722 meningioma cases diagnosed among residents of Connecticut, Massachusetts, California, Texas, and North Carolina from May 1, 2006 through March 14, 2013, and 1622 controls who were frequency matched to the cases by age, sex, and geography. These individuals were participants in a large, population-based, case-control study. Telephone interviews were used to collect data regarding QOL at the time of initial diagnosis or contact, using the Medical Outcomes Study Short-Form 36 Health Survey. QOL outcomes were compared by case/control status. RESULTS: Patients diagnosed with meningioma reported levels of physical, emotional, and mental health functioning below those reported in a general healthy population. Case participants and controls differed most significantly with regard to the domains of Physical and Social Functioning, Role-Physical, Role-Emotional, and Vitality. CONCLUSIONS: In the current study, patients with meningioma experienced statistically significant decreases in QOL compared with healthy controls of a similar demographic breakdown, although these differences were found to vary in clinical significance. Cancer 2018;124:161-6.
BACKGROUND: To the authors' knowledge, limited data exist regarding long-term quality of life (QOL) for patients diagnosed with intracranial meningioma. METHODS: The data in the current study concerned 1722 meningioma cases diagnosed among residents of Connecticut, Massachusetts, California, Texas, and North Carolina from May 1, 2006 through March 14, 2013, and 1622 controls who were frequency matched to the cases by age, sex, and geography. These individuals were participants in a large, population-based, case-control study. Telephone interviews were used to collect data regarding QOL at the time of initial diagnosis or contact, using the Medical Outcomes Study Short-Form 36 Health Survey. QOL outcomes were compared by case/control status. RESULTS:Patients diagnosed with meningioma reported levels of physical, emotional, and mental health functioning below those reported in a general healthy population. Case participants and controls differed most significantly with regard to the domains of Physical and Social Functioning, Role-Physical, Role-Emotional, and Vitality. CONCLUSIONS: In the current study, patients with meningioma experienced statistically significant decreases in QOL compared with healthy controls of a similar demographic breakdown, although these differences were found to vary in clinical significance. Cancer 2018;124:161-6.
Authors: Lorenzo Giammattei; P di Russo; D Starnoni; T Passeri; M Bruneau; T R Meling; M Berhouma; G Cossu; J F Cornelius; D Paraskevopoulos; I Zazpe; E Jouanneau; L M Cavallo; V Benes; V Seifert; M Tatagiba; H W S Schroeder; T Goto; K Ohata; O Al-Mefty; T Fukushima; M Messerer; R T Daniel; S Froelich Journal: Acta Neurochir (Wien) Date: 2021-03-19 Impact factor: 2.216
Authors: Sophie J M Rijnen; Ikram Meskal; Marjan Bakker; Wouter De Baene; Geert-Jan M Rutten; Karin Gehring; Margriet M Sitskoorn Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Silvia Schiavolin; Arianna Mariniello; Morgan Broggi; Francesco DiMeco; Paolo Ferroli; Matilde Leonardi Journal: Support Care Cancer Date: 2022-01-09 Impact factor: 3.359
Authors: Farshad Nassiri; Justin Z Wang; Karolyn Au; Jill Barnholtz-Sloan; Michael D Jenkinson; Kate Drummond; Yueren Zhou; James M Snyder; Priscilla Brastianos; Thomas Santarius; Suganth Suppiah; Laila Poisson; Francesco Gaillard; Mark Rosenthal; Timothy Kaufmann; Derek S Tsang; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2022-05-04 Impact factor: 13.029
Authors: Farshad Nassiri; Benjamin Price; Ameer Shehab; Karolyn Au; Michael D Cusimano; Michael D Jenkinson; Christine Jungk; Alireza Mansouri; Thomas Santarius; Suganth Suppiah; Ken X Teng; Gurvinder S Toor; Gelareh Zadeh; Tobias Walbert; Katharine J Drummond Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Adriana Olar; Lindsey D Goodman; Khalida M Wani; Nicholas S Boehling; Devi S Sharma; Reema R Mody; Joy Gumin; Elizabeth B Claus; Frederick F Lang; Timothy F Cloughesy; Albert Lai; Kenneth D Aldape; Franco DeMonte; Erik P Sulman Journal: Oncotarget Date: 2018-02-15
Authors: Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029